← Leaderboards
Shulin Li
Henry Ford Health System
$17,068,216
Attributed
$21,931,990
Total exposure
13
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,931,990 · 13
By mechanism
R01$19,130,954 · 8
U01$2,022,255 · 1
R21$478,755 · 2
P01$152,173 · 1
R56$147,853 · 1
Top collaborators
- Amy Beth Heimberger10 shared
- Liangfang Zhang5 shared
- Lopa Mishra3 shared
- Kirti Shetty3 shared
- Herbert Yu3 shared
- Linda M S Resar2 shared
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorProteinsCellsGenesInterleukin-12BaseElectroporationMediatingTumor GrowthNeoplastic CellPeptidesRecurrenceMalignant NeoplasmsCause Of DeathT-LymphocyteTreatment EfficacyTissuesGene TherapyNeoplasm MetastasisToxic EffectCytokineFutureGene DeliveryTranslating
Grant awards (66)
Fgl2 neutralizing therapy for inducing tumor specific brain resident immune memory against CNS tumor relapse$589,497
R01 · FY2025 · NS · contact PI
Gene-Product Auto-Targeting to Tumor Vessels$346,275
R01 · FY2025 · CA · contact PI
Fgl2 neutralizing therapy for inducing tumor specific brain resident immune memory against CNS tumor relapse$571,813
R01 · FY2024 · NS · contact PI
Gene-Product Auto-Targeting to Tumor Vessels$328,962
R01 · FY2024 · CA · contact PI
Fgl2 neutralizing therapy for inducing tumor specific brain resident immune memory against CNS tumor relapse$589,497
R01 · FY2023 · NS · contact PI
Gene-Product Auto-Targeting to Tumor Vessels$346,275
R01 · FY2023 · CA · contact PI
Fgl2 neutralizing therapy for inducing tumor specific brain resident immune memory against CNS tumor relapse$589,497
R01 · FY2022 · NS · contact PI
Gene-Product Auto-Targeting to Tumor Vessels$339,350
R01 · FY2022 · CA · contact PI
Fgl2 neutralizing therapy for inducing tumor specific brain resident immune memory against CNS tumor relapse$604,997
R01 · FY2021 · NS · contact PI
Develop CTC capture technology for both mesenchymal and non-mesenchymal tumors$352,800
R01 · FY2021 · EB · contact PI
Gene-Product Auto-Targeting to Tumor Vessels$346,275
R01 · FY2021 · CA · contact PI
Pathway Specific Functional Biomarkers for the Early Detection of Liver Cancer$663,918
U01 · FY2020 · CA
Fgl-2 targeted therapy for reversing multi-modality immune suppression$366,000
R01 · FY2020 · CA · contact PI
Develop CTC capture technology for both mesenchymal and non-mesenchymal tumors$360,000
R01 · FY2020 · EB · contact PI
Tumor-Targeted Chemo-Immunotherapy for Osteosarcoma Metastasis$359,138
R01 · FY2020 · CA
Pathway Specific Functional Biomarkers for the Early Detection of Liver Cancer$647,886
U01 · FY2019 · CA
Low Electric Field-Based Gene Delivery of IL-30 Gene Therapy for Liver Injury$360,000
R01 · FY2019 · DK · contact PI
Develop CTC capture technology for both mesenchymal and non-mesenchymal tumors$360,000
R01 · FY2019 · EB · contact PI
Fgl-2 targeted therapy for reversing multi-modality immune suppression$355,019
R01 · FY2019 · CA · contact PI
Tumor-Targeted Chemo-Immunotherapy for Osteosarcoma Metastasis$348,363
R01 · FY2019 · CA
Pathway Specific Functional Biomarkers for the Early Detection of Liver Cancer$710,451
U01 · FY2018 · CA
Fgl-2 targeted therapy for reversing multi-modality immune suppression$366,000
R01 · FY2018 · CA · contact PI
Low Electric Field-Based Gene Delivery of IL-30 Gene Therapy for Liver Injury$360,000
R01 · FY2018 · DK · contact PI
Develop CTC capture technology for both mesenchymal and non-mesenchymal tumors$360,000
R01 · FY2018 · EB · contact PI
Tumor-Targeted Chemo-Immunotherapy for Osteosarcoma Metastasis$359,138
R01 · FY2018 · CA
Fgl-2 targeted therapy for reversing multi-modality immune suppression$366,000
R01 · FY2017 · CA · contact PI
Low Electric Field-Based Gene Delivery of IL-30 Gene Therapy for Liver Injury$360,000
R01 · FY2017 · DK · contact PI
Tumor-Targeted Chemo-Immunotherapy for Osteosarcoma Metastasis$359,138
R01 · FY2017 · CA
Tumor-Targeted Chemo-Immunotherapy for Osteosarcoma Metastasis$372,888
R01 · FY2016 · CA
Fgl-2 targeted therapy for reversing multi-modality immune suppression$366,000
R01 · FY2016 · CA · contact PI
Low Electric Field-Based Gene Delivery of IL-30 Gene Therapy for Liver Injury$360,000
R01 · FY2016 · DK · contact PI
Gene-Product Auto-Targeting to Tumor Vessels$291,194
R01 · FY2016 · CA · contact PI
Low Electric Field-Based Gene Delivery of IL-30 Gene Therapy for Liver Injury$360,000
R01 · FY2015 · DK · contact PI
Gene-Product Auto-Targeting to Tumor Vessels$291,194
R01 · FY2015 · CA · contact PI
IL12 Gene Therapy For Enhancing Therapeutic Efficacy of Bleomycin Against Oral Tu$308,475
R01 · FY2014 · CA · contact PI
Gene-Product Auto-Targeting to Tumor Vessels$282,458
R01 · FY2014 · CA · contact PI
IL12 Gene Therapy For Enhancing Therapeutic Efficacy of Bleomycin Against Oral Tu$298,935
R01 · FY2013 · CA · contact PI
Elimination of residual malignancy by programmed systemic cytokine gene therapy$293,107
R01 · FY2013 · CA · contact PI
Gene-Product Auto-Targeting to Tumor Vessels$273,722
R01 · FY2013 · CA · contact PI
Cell Culture and Tissue Morphology Core$152,173
P01 · FY2013 · CA · contact PI
IL12 Gene Therapy For Enhancing Therapeutic Efficacy of Bleomycin Against Oral Tu$318,015
R01 · FY2012 · CA · contact PI
Elimination of residual malignancy by programmed systemic cytokine gene therapy$311,816
R01 · FY2012 · CA · contact PI
Gene-Product Auto-Targeting to Tumor Vessels$291,194
R01 · FY2012 · CA · contact PI
IL12 Gene Therapy For Enhancing Therapeutic Efficacy of Bleomycin Against Oral Tu$318,015
R01 · FY2011 · CA · contact PI
Elimination of residual malignancy by programmed systemic cytokine gene therapy$311,816
R01 · FY2011 · CA · contact PI
Gene-Product Auto-Targeting to Tumor Vessels$291,194
R01 · FY2011 · CA · contact PI
IL12 Gene Therapy For Enhancing Therapeutic Efficacy of Bleomycin Against Oral Tu$327,850
R01 · FY2010 · CA · contact PI
Elimination of residual malignancy by programmed systemic cytokine gene therapy$321,460
R01 · FY2010 · CA · contact PI
Gene-Product Auto-Targeting to Tumor Vessels$300,200
R01 · FY2010 · CA · contact PI
Gene-Product Auto-Targeting to Tumor Vessels$181,006
R01 · FY2010 · CA · contact PI
Elimination of residual malignancy by programmed systemic cytokine gene therapy$301,115
R01 · FY2009 · CA · contact PI
Gene-Product Auto-Targeting to Tumor Vessels$279,300
R01 · FY2009 · CA · contact PI
Gene-Product Auto-Targeting to Tumor Vessels$38,397
R01 · FY2009 · CA · contact PI
Gene-Product Auto-Targeting to Tumor Vessels$279,300
R01 · FY2008 · CA · contact PI
Novel gene delivery and expression system$183,750
R21 · FY2008 · EB · contact PI
Elimination of residual malignancy by programmed systemic cytokine gene therapy$147,853
R56 · FY2008 · CA · contact PI
Gene-Product Auto-Targeting to Tumor Vessels$279,300
R01 · FY2007 · CA · contact PI
Electro-injection of IL-12 DNA to Muscle for Cancer$143,546
R01 · FY2006 · CA · contact PI
Electro-injection of IL-12 DNA to Muscle for Cancer$327,075
R01 · FY2005 · CA
Electro-injection of IL-12 DNA to Muscle for Cancer$327,075
R01 · FY2004 · CA
Electro-injection of IL-12 DNA to Muscle for Cancer$327,075
R01 · FY2003 · CA
Tumor-targeted electroporation gene therapy$147,000
R21 · FY2003 · DE
Electro-injection of IL-12 DNA to Muscle for Cancer$306,154
R01 · FY2002 · CA
Tumor-targeted electroporation gene therapy$143,000
R21 · FY2002 · DE
Electro-injection of IL-12 DNA to Muscle for Cancer$8,044
R01 · FY2002 · CA
Tumor-targeted electroporation gene therapy$5,005
R21 · FY2002 · DE